IGM Biosciences, Inc.
IGM Biosciences, Inc. (IGMS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
igms · stock forecast · 18 analysts (3M) · FMP · updated Oct 31, 2025
Analyst Rating & Consensus
Based on 18 Wall Street analysts in the past 3 months
Hold
18 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$31.00
Consensus
$16.79
+1222.0% upside
Low
$1.50
Median: $21 · Last Close: $1.27
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.27 | ↑ 0.10% |
1-day model range: $1.26–$1.28. Peak: $1.28 (+0.10%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · IGMS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-11 | Truist Securities | Maintains | Hold→Hold |
| 2025-01-13 | JP Morgan | Upgrade ↑ | Underweight→Neutral |
| 2025-01-10 | Stifel | Downgrade ↓ | Buy→Hold |
| 2025-01-10 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2025-01-10 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-01-10 | Truist Securities | Maintains | Hold→Hold |
| 2025-01-10 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2024-11-11 | Stifel | Maintains | Buy→Buy |
| 2024-10-18 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-10-01 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
Wall Street analysts have recently issued updated ratings on IGM Biosciences, Inc. (IGMS) stock. Of the recent 82 rating actions, 3 were upgrades and 12 were downgrades. 18 analysts currently cover IGMS.
Analyst Recommendation Trends
IGMS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$9M
↓ 33.7% YoY
Revenue Next Year
$14M
↑ 46.6% YoY
EPS This Year
$-1.65
EPS Next Year
$-1.40
↓ 15.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast IGMS EPS of $-1.65 for the current fiscal year, based on estimates from 2 analysts. The IGMS revenue forecast is $9M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IGMS stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IGMS price target is $16.79 (+1222.0% upside), with an analyst consensus of Hold.
The IGMS short-term stock prediction for tomorrow is $1.27 (+0.10%).
IGM Biosciences, Inc. trades on NASDAQ under the ticker IGMS. The IGMS stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 44% of covering analysts.
Frequently asked questions
IGMS forecast · 8 questionsAccording to 18 Wall Street analysts, the average 12-month IGMS price target is $16.79, with a high forecast of $31.00 and a low of $1.50. The median price target is shown in the chart above when available. This implies +1222.0% potential upside from the current price of $1.27.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.